Immunosignature: Serum antibody profiling for cancer diagnostics

Andrei Chapoval, J. Bart Legutki, Phillip Stafford, Andrey V. Trebukhov, Stephen Johnston, Yakov N. Shoikhet, Alexander F. Lazarev

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Biomarkers for preclinical diagnosis of cancer are valuable tools for detection of malignant tumors at early stages in groups at risk and screening healthy people, as well as monitoring disease recurrence after treatment of cancer. However the complexity of the body's response to the pathological processes makes it virtually impossible to evaluate this response to the development of the disease using a single biomarker that is present in the serum at low concentrations. An alternative approach to standard biomarker analysis is called immunosignature. Instead of going after biomarkers themselves this approach rely on the analysis of the humoral immune response to molecular changes associated with the development of pathological processes. It is known that antibodies are produced in response to proteins expressed during cancer development. Accordingly, the changes in antibody repertoire associated with tumor growth can serve as biomarkers of cancer. Immunosignature is a highly sensitive method for antibody repertoire analysis utilizing high density peptide microarrays. In the present review we discuss modern methods for antibody detection, as well as describe the principles and applications of immunosignature in research and clinical practice.

Original languageEnglish (US)
Pages (from-to)4833-4837
Number of pages5
JournalAsian Pacific Journal of Cancer Prevention
Volume16
Issue number12
DOIs
StatePublished - 2015

Fingerprint

Biomarkers
Antibodies
Serum
Pathologic Processes
Neoplasms
Tumor Biomarkers
Humoral Immunity
Recurrence
Peptides
Growth
Research
Proteins

Keywords

  • Antibodies
  • Autoantibodies
  • Biomarkers
  • Cancer
  • Diagnostics
  • Immunosignature
  • Peptide microarray

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Public Health, Environmental and Occupational Health
  • Epidemiology

Cite this

Immunosignature : Serum antibody profiling for cancer diagnostics. / Chapoval, Andrei; Legutki, J. Bart; Stafford, Phillip; Trebukhov, Andrey V.; Johnston, Stephen; Shoikhet, Yakov N.; Lazarev, Alexander F.

In: Asian Pacific Journal of Cancer Prevention, Vol. 16, No. 12, 2015, p. 4833-4837.

Research output: Contribution to journalArticle

Chapoval, Andrei ; Legutki, J. Bart ; Stafford, Phillip ; Trebukhov, Andrey V. ; Johnston, Stephen ; Shoikhet, Yakov N. ; Lazarev, Alexander F. / Immunosignature : Serum antibody profiling for cancer diagnostics. In: Asian Pacific Journal of Cancer Prevention. 2015 ; Vol. 16, No. 12. pp. 4833-4837.
@article{f37df83ca97e4033829985a41bd718b1,
title = "Immunosignature: Serum antibody profiling for cancer diagnostics",
abstract = "Biomarkers for preclinical diagnosis of cancer are valuable tools for detection of malignant tumors at early stages in groups at risk and screening healthy people, as well as monitoring disease recurrence after treatment of cancer. However the complexity of the body's response to the pathological processes makes it virtually impossible to evaluate this response to the development of the disease using a single biomarker that is present in the serum at low concentrations. An alternative approach to standard biomarker analysis is called immunosignature. Instead of going after biomarkers themselves this approach rely on the analysis of the humoral immune response to molecular changes associated with the development of pathological processes. It is known that antibodies are produced in response to proteins expressed during cancer development. Accordingly, the changes in antibody repertoire associated with tumor growth can serve as biomarkers of cancer. Immunosignature is a highly sensitive method for antibody repertoire analysis utilizing high density peptide microarrays. In the present review we discuss modern methods for antibody detection, as well as describe the principles and applications of immunosignature in research and clinical practice.",
keywords = "Antibodies, Autoantibodies, Biomarkers, Cancer, Diagnostics, Immunosignature, Peptide microarray",
author = "Andrei Chapoval and Legutki, {J. Bart} and Phillip Stafford and Trebukhov, {Andrey V.} and Stephen Johnston and Shoikhet, {Yakov N.} and Lazarev, {Alexander F.}",
year = "2015",
doi = "10.7314/APJCP.2015.16.12.4833",
language = "English (US)",
volume = "16",
pages = "4833--4837",
journal = "Asian Pacific Journal of Cancer Prevention",
issn = "1513-7368",
publisher = "Asian Pacific Organization for Cancer Prevention",
number = "12",

}

TY - JOUR

T1 - Immunosignature

T2 - Serum antibody profiling for cancer diagnostics

AU - Chapoval, Andrei

AU - Legutki, J. Bart

AU - Stafford, Phillip

AU - Trebukhov, Andrey V.

AU - Johnston, Stephen

AU - Shoikhet, Yakov N.

AU - Lazarev, Alexander F.

PY - 2015

Y1 - 2015

N2 - Biomarkers for preclinical diagnosis of cancer are valuable tools for detection of malignant tumors at early stages in groups at risk and screening healthy people, as well as monitoring disease recurrence after treatment of cancer. However the complexity of the body's response to the pathological processes makes it virtually impossible to evaluate this response to the development of the disease using a single biomarker that is present in the serum at low concentrations. An alternative approach to standard biomarker analysis is called immunosignature. Instead of going after biomarkers themselves this approach rely on the analysis of the humoral immune response to molecular changes associated with the development of pathological processes. It is known that antibodies are produced in response to proteins expressed during cancer development. Accordingly, the changes in antibody repertoire associated with tumor growth can serve as biomarkers of cancer. Immunosignature is a highly sensitive method for antibody repertoire analysis utilizing high density peptide microarrays. In the present review we discuss modern methods for antibody detection, as well as describe the principles and applications of immunosignature in research and clinical practice.

AB - Biomarkers for preclinical diagnosis of cancer are valuable tools for detection of malignant tumors at early stages in groups at risk and screening healthy people, as well as monitoring disease recurrence after treatment of cancer. However the complexity of the body's response to the pathological processes makes it virtually impossible to evaluate this response to the development of the disease using a single biomarker that is present in the serum at low concentrations. An alternative approach to standard biomarker analysis is called immunosignature. Instead of going after biomarkers themselves this approach rely on the analysis of the humoral immune response to molecular changes associated with the development of pathological processes. It is known that antibodies are produced in response to proteins expressed during cancer development. Accordingly, the changes in antibody repertoire associated with tumor growth can serve as biomarkers of cancer. Immunosignature is a highly sensitive method for antibody repertoire analysis utilizing high density peptide microarrays. In the present review we discuss modern methods for antibody detection, as well as describe the principles and applications of immunosignature in research and clinical practice.

KW - Antibodies

KW - Autoantibodies

KW - Biomarkers

KW - Cancer

KW - Diagnostics

KW - Immunosignature

KW - Peptide microarray

UR - http://www.scopus.com/inward/record.url?scp=84937053510&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937053510&partnerID=8YFLogxK

U2 - 10.7314/APJCP.2015.16.12.4833

DO - 10.7314/APJCP.2015.16.12.4833

M3 - Article

C2 - 26163599

AN - SCOPUS:84937053510

VL - 16

SP - 4833

EP - 4837

JO - Asian Pacific Journal of Cancer Prevention

JF - Asian Pacific Journal of Cancer Prevention

SN - 1513-7368

IS - 12

ER -